All articles by Divya Tirumalaraju

Divya Tirumalaraju

University of Sheffield tests available drugs for incurable breast cancer

The trial will involve 42 patients whose breast cancer has spread to other parts of the body.

Elligo Health acquires clinical services firm ClinEdge for $135m

The acquisition, which also includes GuideStar Research and BTC of New Bedford, was financed through investor funding.

PathAI and Summit Clinical offer new solution for NASH trials

The companies will address high costs for site activation and enrolment barriers linked to NASH drug trials.

Trialbee collaborates with Castor to boost access to trials

The partners will facilitate diversified participation and improve health equity for decentralised and hybrid clinical trials.

Gritstone starts Phase I dosing of second-gen mRNA Covid-19 vaccine

The trial will test the safety, tolerability and immunogenicity of two dose levels of the vaccine given as a booster to Vaxzevria.

UK trial to assess mixed Covid-19 vaccine regimens in adolescents

Subjects will receive a first dose of the Pfizer-BioNTech vaccine and a second dose of either Pfizer, Novavax or Moderna.

Biogen reports positive Phase II data of non-opioid pain drug in SFN

Vixotrigine 200mg dose met the primary endpoint while 350mg failed to achieve the goal, with both doses being well tolerated.

Aerie’s dry eye therapeutic improves symptoms and signs in Phase IIb trial

A statistically significant improvement in symptoms and signs was observed at day 14 and sustained through day 84.

City of Hope trials Covid-19 vaccine in immunocompromised patients

The trial is the first to compare a Covid-19 vaccine candidate with Pfizer’s Covid-19 vaccine in this patient population.

AIVITA finds personalised Covid-19 vaccine generates immune response

In 96% of participants, vaccination led to an enhanced immune memory response against the Covid-19 virus.